Microbot Medical Inc. (MBOT): Price and Financial Metrics

Microbot Medical Inc. (MBOT): $2.23

0.21 (+10.40%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add MBOT to Watchlist
Sign Up

MBOT Price/Volume Stats

Current price $2.23 52-week high $6.33
Prev. close $2.02 52-week low $1.00
Day low $1.97 Volume 1,335,300
Day high $2.33 Avg. volume 2,167,089
50-day MA $1.72 Dividend yield N/A
200-day MA $3.39 Market Cap 18.13M

MBOT Stock Price Chart Interactive Chart >


Microbot Medical Inc. (MBOT) Company Bio


Microbot Medical Inc. operates as a medical device company. The Company specializes in the research, design, development, and commercialization of micro-robotics assisted medical technologies. Microbot Medical offers its services in the United States.


MBOT Latest News Stream


Event/Time News Detail
Loading, please wait...

MBOT Latest Social Stream


Loading social stream, please wait...

View Full MBOT Social Stream

Latest MBOT News From Around the Web

Below are the latest news stories about MICROBOT MEDICAL INC that investors may wish to consider to help them evaluate MBOT as an investment opportunity.

Microbot Medical Announces $1.5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 701,756 shares of the Company’s common stock at a purchase price of $2.1375 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered series C preferred investment options. The series C preferred

Yahoo | June 2, 2023

Microbot Medical Receives a Non-Dilutive Grant from The Israel Innovation Authority Supporting the Development of the Manufacturing Process for its Endovascular Surgical Robotic System

HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic surgical system, announced it has received a grant from the Israel Innovation Authority ("IIA”) in the amount of NIS 1.62 million, which based on a recent exchange rate to the U.S. dollar, would be approximately $440,000, to further support the development of the Company’s manufacturing process of its flagship rob

Yahoo | June 2, 2023

LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process

The data collected from the usage and experience of the medical professionals in the formative study will be used to support the Company's anticipated milestonesHINGHAM, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular surgical robotic system, announces that an additional milestone was achieved when medical professionals experienced the Company's LIBERTY Robotic Surgical System a

Yahoo | May 31, 2023

Lahey Hospital & Medical Center Agrees to become One of the U.S. Sites for the LIBERTY® Robotic System’s First Human Trial

This Significant Achievement Represents Major Progression Toward Regulatory and Commercialization Paths Additional Sites in the U.S. Are Expected to Participate in the Trial HINGHAM, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has successfully achieved another major milestone representing the next step toward the regulatory and commercial paths for the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system. Lahey Hosp

Yahoo | May 25, 2023

Microbot Medical Announces Closing of $2.66 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,209,500 shares of the Company’s common stock (or common stock equivalents) at a purchase price of $2.20 per share of common stock priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to the Company from the off

Yahoo | May 24, 2023

Read More 'MBOT' Stories Here

MBOT Price Returns

1-mo 100.90%
3-mo -12.89%
6-mo -45.61%
1-year -62.90%
3-year -69.20%
5-year -82.09%
YTD -25.91%
2022 -59.87%
2021 8.85%
2020 -32.25%
2019 491.28%
2018 -88.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!